TimesSquare Capital Management LLC Buys 144,516 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

TimesSquare Capital Management LLC raised its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 53.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 413,637 shares of the company’s stock after acquiring an additional 144,516 shares during the quarter. TimesSquare Capital Management LLC’s holdings in Vaxcyte were worth $33,860,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of the business. CIBC Asset Management Inc boosted its stake in shares of Vaxcyte by 5.5% during the 4th quarter. CIBC Asset Management Inc now owns 3,307 shares of the company’s stock worth $271,000 after acquiring an additional 171 shares during the last quarter. Sanctuary Advisors LLC boosted its stake in shares of Vaxcyte by 28.1% during the 4th quarter. Sanctuary Advisors LLC now owns 5,685 shares of the company’s stock worth $465,000 after acquiring an additional 1,248 shares during the last quarter. AlphaCentric Advisors LLC purchased a new position in shares of Vaxcyte during the 4th quarter worth $161,000. Principal Financial Group Inc. boosted its stake in shares of Vaxcyte by 486.2% during the 4th quarter. Principal Financial Group Inc. now owns 308,939 shares of the company’s stock worth $25,290,000 after acquiring an additional 256,237 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D boosted its stake in shares of Vaxcyte by 13.7% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 44,901 shares of the company’s stock worth $3,676,000 after acquiring an additional 5,427 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insiders Place Their Bets

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total value of $710,240.00. Following the sale, the chief financial officer now owns 109,491 shares in the company, valued at $9,720,610.98. The trade was a 6.81 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Teri Loxam sold 6,250 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the sale, the director now owns 7,175 shares in the company, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 68,616 shares of company stock worth $6,095,681 in the last 90 days. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Trading Down 1.8 %

Shares of PCVX stock opened at $82.47 on Wednesday. Vaxcyte, Inc. has a 52 week low of $58.10 and a 52 week high of $121.06. The company’s fifty day simple moving average is $86.03 and its two-hundred day simple moving average is $94.73.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PCVX. Needham & Company LLC reiterated a “buy” rating and set a $14.00 price target on shares of Vaxcyte in a research note on Tuesday, February 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 target price on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $127.71.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.